

Applicants: Arlindo L. Castelhana et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 11

Remarks

Claims 1-59 were pending in the subject application. By this Amendment, Applicants have canceled claims 1-41. Accordingly, claims 42-59 are currently pending.

The subject application claims the benefit of U.S. Application No. 10/000,280, filed November 30, 2001. The issue fee was paid in connection with U.S. Serial No. 10/000,280 on November 5, 2003, however, the patent has not yet issued. Consequently, U.S. Application No. 10/000,280 is pending today and this continuation application is being timely filed.

Applicants note that the specification of the subject application differs from that of U.S. Application No. 10/000,280, from which the subject application claims priority, in that the specification has been amended to incorporate the amendments introduced into the specification of U.S. Application No. 10/000,280 during prosecution. In addition, the specification has been amended to correct several typographical errors and to conform the structures of Scheme IV with the description appearing on pages 100-101. No new matter has been introduced.

The paragraphs added to the subject specification on page 45 are taken from pages 355-358 of R.B. Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action," Academic Press, Chapter 8, which is incorporated by reference on page 45, line 7 of the specification. A copy of the aforementioned pages is attached hereto as **Exhibit A**. No new matter is introduced.